Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Reexamination Certificate
2006-07-18
2006-07-18
Priebe, Scott D. (Department: 1633)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
C424S187100, C424S199100, C424S207100, C530S395000, C435S320100
Reexamination Certificate
active
07078483
ABSTRACT:
A retroviral vector comprising a first retroviral envelope protein and at least one modified retroviral envelope protein, wherein the first retroviral envelope protein includes a surface protein comprising (i) a receptor binding region; (ii) a hypervariable polyproline region; and (iii) a body portion, and the modified retroviral envelope protein, prior to modification, includes a surface protein which includes (i) a receptor binding region; (ii) a hypervariable polyproline region; and (iii) a body portion, characterized in that the modified retroviral envelope protein has been modified such that at least 90% of the amino acid residues of the receptor binding region of the surface protein of the modified retroviral envelope protein have been removed and replaced with a non-retroviral protein or peptide.
REFERENCES:
patent: 5354674 (1994-10-01), Hodgson
patent: 5512421 (1996-04-01), Burns et al.
patent: 5543328 (1996-08-01), McClelland et al.
patent: 5591624 (1997-01-01), Barber et al.
patent: 5643770 (1997-07-01), Mason et al.
patent: 5681746 (1997-10-01), Bodner et al.
patent: 5695991 (1997-12-01), Lindholm et al.
patent: 5985655 (1999-11-01), Anderson et al.
patent: 6004798 (1999-12-01), Anderson et al.
patent: 0 334 301 (1989-09-01), None
patent: WO 91/02805 (1991-03-01), None
patent: WO 92/06180 (1992-04-01), None
patent: WO 92/014829 (1992-09-01), None
patent: WO 92/20316 (1992-11-01), None
patent: WO 93/00103 (1993-01-01), None
patent: WO 93/09221 (1993-05-01), None
patent: WO 93/14188 (1993-07-01), None
patent: WO 93/25234 (1993-12-01), None
patent: WO 94/06920 (1994-03-01), None
patent: WO 94/10323 (1994-05-01), None
patent: WO 94/11524 (1994-05-01), None
patent: WO 95/23846 (1995-09-01), None
patent: WO 96/30504 (1996-10-01), None
patent: WO 97/24446 (1997-07-01), None
patent: WO 99/55893 (1999-11-01), None
Han, X. et al., “Ligand-directed retroviral targeting of human breast cancer cells”, 1995, PNAS, vol. 92: pp. 9747-9751.
Ohno, K. et al., “Retrovirus Vectors Displaying the IgG-Binding Domain of Protein A”, Oct. 1997, Biochem. and Mol. Med., vol. 62: pp. 123-127.
Chu, Te-Hua Tearina et al., Cell Targeting WIth Retroviral Vector Particles Containing Antibody-Envelope Fusion Proteins,Gene Therapy(1994) 1, pp. 292-299.
Arap, et al., “Cancer Treatment by Targeted Drug Delivery to Tumor Vasculature in a Mouse Model,”Science, 279:377-380 (Jan. 1980).
Barinaga, “Step Taken Toward Improved Vectors for Gene Transfer,”Science, 266:1326 (Nov. 25, 1994).
Bender, et al., “Evidence that the Packaging Signal of Moloney Murine Leukemia Virus Extends into the Gag Region,”J. Virol, 61(5):1639-1646 (May 1987).
Cosset, et al., “Retroviral Retargeting by Envelopes Expressing an N-Terminal Binding Doman,”J. Virol., 69(10):6314-6322 (Oct. 1995).
Hall, et al., “Molecular Engineering Matrix-Targeted Retroviral Vectors Incorporating a Surveillance Funcint Inherent in von Willebrand Factor,”Human Geme Therapy, 11:983-993 (May 1, 2000).
Hall, et al., “Molecular Engineering of Targeted Retroviral Vectors: Concepts, Development, and Applications,” Presentation: Cold Spring Harbor Meeting, Vector Targeting Strategies for Therapeutic Gene Delivery, Mar. 11-14, 1999.
Hall, et al., “Targeting Retroviral Vectors to Vascular Lesions by genetic Engineering of the MoMLV gp70 Envelope Protein,”Human Gene Therapy, 8:2183-2192 (Dec. 10, 1997).
Han, et al., “Chimeric Envelope Glycoproteins Constructed Between Amphotropic and Xenotropic Murine Leukemia Retroviruses,”Som. Cell and Mol. Genetics, 21(3):205-214 (1995).
Kadan, et al., “Detection of Receptor-Specific Murine Leukemia Virus Binding to Cells by Immunofluorescence Analysis,”J. Virol., 66(4):2281-2287 (Apr. 1992).
Kasahara, et al., “Tissue-Specific Targeting of Retroviral Vectors Through Ligand-Receptor Interactions,”Science, 266: 1373-1376 (Nov. 25, 1994).
Martin, et al., “Retroviral Vector Targeting to Melanoma Cells by Single-Chain Antibody Incorporation in Envelope,”Human Gene Therapy, 9:737-746 (Mar. 20, 1998).
Miller, et al., “Improved Retroviral Vectors for Gene Transfer and Expression,”Biotechniques, 7(9):980-990 (1989).
Russell, et al., “Retroviral Vectors Displaying Functional Antibody Fragments,”Nucleic Acids Research, 21(5): 1081-1085 (1993).
Somia, et al., “Generation of Targeted Retroviral Vectors by Using Single-Chain Variable Fragment: An Approach to in vivo Gene Delivery,”Proc. Natl. Acad. Sci. USA, 92:7570-7574 (Aug. 1995).
Anderson W. French
Gordon Erlinda Maria
Hall Frederick L.
Burkhart Michael
Priebe Scott D.
University of Southern California
Wilson Sonsini Goodrich & Rosati
LandOfFree
Retroviral vectors including modified envelope escort proteins does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Retroviral vectors including modified envelope escort proteins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Retroviral vectors including modified envelope escort proteins will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3540625